NCT02472665 - Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

April 30, 2025

Study Completion Date

December 31, 2026

Conditions

Von Willebrand Disease

Interventions

DRUG

plasma-derived FVIII/VWF concentrate

1 single dose of 80 IU/kg VWF:RCo of Fanhdi will be administered

Trial Locations (4)

RECRUITING

Hospital Universitario Virgen del Rocío, Seville

RECRUITING

Hospital Sant Joan de Déu Barcelona, Esplugues de Llobregat

RECRUITING

Hospital Universitario La Paz, Madrid

RECRUITING

Hospital Universitario Miguel Servet, Zaragoza